Price T Rowe Associates Inc Pharvaris N.V. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Pharvaris N.V. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 767,315 shares of PHVS stock, worth $16.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
767,315
Previous 586,087
30.92%
Holding current value
$16.2 Million
Previous $9.2 Million
46.76%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PHVS
# of Institutions
58Shares Held
39.2MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY7.53MShares$159 Million4.61% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.41MShares$93 Million85.48% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$90.5 Million79.45% of portfolio
-
Viking Global Investors LP3.65MShares$77 Million0.2% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA3.3MShares$69.7 Million17.44% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $712M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...